CD274 and non-small cell lung carcinoma: Thus, checkpoint therapies should not be completely excluded from candidate strategies for the treatment of NSCLC patients who acquire resistance to EGFR-TKIs, and unfolding the regulatory mechanisms of PD-L1 in EGFR-TKI resistant NSCLC is thus imperative.